Phase1 study of OCV-105 in patients with pancreatic cancer refractory or intolerable to standard therapy
Phase of Trial: Phase I
Latest Information Update: 12 May 2016
At a glance
- Drugs OCV 105 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 12 Jun 2012 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 31 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 03 Aug 2011 New trial record